https://www.selleckchem.com/pr....oducts/fezolinetant.
There is a high prevalence of liver injury (LI) in patients with coronavirus disease 2019 (COVID-19); however, few large-scale studies assessing risk factors and clinical outcomes in these patients have been done. To evaluate the risk factors and clinical outcomes associated with LI in a large inpatient cohort of COVID-19 patients. Adult patients with COVID-19 between March 1 and April 30, 2020, were included. LI was defined as peak levels of alanine aminotransferase/aspartate aminotransferase that were 3 times the ULN or peak leve
Like
Comment
Share
